Test Definition: IGFG Insulin-Like Growth Factor 1 (IGF-1) and Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) Growth Panel

Size: px
Start display at page:

Download "Test Definition: IGFG Insulin-Like Growth Factor 1 (IGF-1) and Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) Growth Panel"

Transcription

1 Reporting Title: IGF-1 and IGFBP-3 Growth Panel Performing Location: Rochester Specimen Requirements: Collection Container/Tube: Preferred: Red top Acceptable: Serum gel Submission Container/Tube: Plastic vial Specimen Volume: 1 ml Collection Instructions: Spin down promptly. Aliquot into two equal portions. Additional Information: Indicate patient's age and sex. Specimen Type Temperature Time Serum Frozen 14 days Result Codes: Result ID Reporting Name Type Unit LOINC IGF1I Insulin-Like Growth Factor 1, S Numeric ng/ml In Process IGFB3 IGFBP-3, S Numeric mcg/ml Also used by tests: IGFB3 Components: Test ID Reporting Name CPT Units CPT Code Always Performed Orderable Separately IGF1I Insulin-Like Growth Factor 1, S Yes Yes IGFB3 IGFBP-3, S Yes Yes Reference Values: Males: Age ng/ml 0.1 Percentile (ng/ml) 0-11 months Document generated January 22, 2013 at 4:31pm CST Page 1 of 5

2 1 year years years years years years years years years years years years years years years years years years years years years years years years years years years years years years years years Document generated January 22, 2013 at 4:31pm CST Page 2 of 5

3 80-85 years years Females: Age ng/ml 0.1 Percentile (ng/ml) 0-11 months year years years years years years years years years years years years years years years years years years years years years years years years years years Document generated January 22, 2013 at 4:31pm CST Page 3 of 5

4 51-55 years years years years years years years years Reference values have not been established for patients that are >90 years of age. IGF-1 reference values according to Tanner stages I-V(2) Males - Stage I: ng/ml - Stage II: ng/ml - Stage III: ng/ml - Stage IV: ng/ml - Stage V: ng/ml Females - Stage I: ng/ml - Stage II: ng/ml - Stage III: ng/ml - Stage IV: ng/ml - Stage V: ng/ml Note: Puberty onset, ie the transition from Tanner stage 1 (prepubertal) to Tanner stage 2 (early pubertal), occurs for girls at a median age of 10.5 (+/- 2) years and for boys at a median age of 11.5 (+/-2) years. There is evidence that it may occur up to 1 year earlier in obese girls and in African-American girls. By contrast, for boys there is no definite proven relationship between puberty onset and body weight or ethnic origin. Progression through Tanner stages is variable. Tanner stage 5 (young adult) should be reached by age 18. INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN days: < or =0.7 mcg/ml 8-14 days: mcg/ml 15 days-11 months: unavailable 1 year: mcg/ml 2 years: mcg/ml 3 years: mcg/ml 4 years: mcg/ml 5 years: mcg/ml 6 years: mcg/ml 7 years: mcg/ml 8 years: mcg/ml 9 years: mcg/ml 10 years: mcg/ml 11 years: mcg/ml 12 years: mcg/ml Document generated January 22, 2013 at 4:31pm CST Page 4 of 5

5 13 years: mcg/ml 14 years: mcg/ml 15 years: mcg/ml 16 years: mcg/ml 17 years: mcg/ml 18 years: mcg/ml 19 years: mcg/ml 20 years: mcg/ml years: mcg/ml years: mcg/ml years: mcg/ml years: mcg/ml years: mcg/ml years: mcg/ml years: mcg/ml years: mcg/ml years: mcg/ml years: mcg/ml years: mcg/ml years: mcg/ml years: mcg/ml Tanner Stages: Males Stage I: mcg/ml Stage II: mcg/ml Stage III: mcg/ml Stage IV: mcg/ml Stage V: mcg/ml Females Stage I: mcg/ml Stage II: mcg/ml Stage III: mcg/ml Stage IV: mcg/ml Stage V: mcg/ml Note: Puberty onset, ie the transition from Tanner stage 1 (prepubertal) to Tanner stage 2 (early pubertal), occurs for girls at a median age of 10.5 (+/- 2) years and for boys at a median age of 11.5 (+/-2) years. There is evidence that it may occur up to 1 year earlier in obese girls and in African-American girls. By contrast, for boys there is no definite proven relationship between puberty onset and body weight or ethnic origin. Progression through Tanner stages is variable. Tanner stage 5 (young adult) should be reached by age 18. Document generated January 22, 2013 at 4:31pm CST Page 5 of 5

Result ID Reporting Name Type Unit LOINC. Z1886 Cortisol Alphanumeric ug/dl Z0226 Deoxycorticosterone (DOC) Alphanumeric ng/dl

Result ID Reporting Name Type Unit LOINC. Z1886 Cortisol Alphanumeric ug/dl Z0226 Deoxycorticosterone (DOC) Alphanumeric ng/dl Reporting Title: CAH Profile 6 Performing Location: Esoterix Endocrinol Specimen Requirements: Draw blood in a plain, red-top tube(s). Spin down and separate within 1 hour of collection and send 3.5 ml

More information

Test Definition: FNMR2 NMR LipoProfile w/ir Markers

Test Definition: FNMR2 NMR LipoProfile w/ir Markers Reporting Title: Performing Location: Labcorp Burlington Specimen Requirements: Submit only one of the following specimens: Serum Draw blood in a plain red-top tube(s). (Serum gel tube is not acceptable.)

More information

Test Definition: PCDSO Pain Clinic Drug Screen, Urine

Test Definition: PCDSO Pain Clinic Drug Screen, Urine Reporting Title: Pain Clinic Drug Screen, U Performing Location: Rochester Specimen Requirements: Collection Container/Tube: Plastic urine container Submission Container/Tube: Plastic, 60-mL urine bottle

More information

Test Definition: PDSOX Pain Clinic Drug Screen, Chain of Custody, Urine

Test Definition: PDSOX Pain Clinic Drug Screen, Chain of Custody, Urine Reporting Title: Pain Clinic Drug Screen, CoC, U Performing Location: Rochester Specimen Requirements: Container/Tube: Chain-of-Custody Kit (Supply T282) containing the specimen containers, seals, and

More information

Test Definition: LCMS Leukemia/Lymphoma Immunophenotyping by Flow Cytometry

Test Definition: LCMS Leukemia/Lymphoma Immunophenotyping by Flow Cytometry Reporting Title: Leukemia/Lymphoma, Phenotype Performing Location: Rochester Advisory Information: This test is appropriate for hematopoietic specimens only. If your specimen is a solid tissue, order LLPT

More information

Test Definition: HBELC Hemoglobin Electrophoresis Cascade, Blood

Test Definition: HBELC Hemoglobin Electrophoresis Cascade, Blood Reporting Title: HGB Electrophoresis Cascade Performing Location: Rochester Advisory Information: Alpha-thalassemias with only 1 or 2 alpha-globin gene deletions are not recognized by this testing protocol.

More information

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)? Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Growth Hormone (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and

More information

Test Definition: FMCPS Meningoencephalitis Comprehensive Panel (Serum)

Test Definition: FMCPS Meningoencephalitis Comprehensive Panel (Serum) Reporting Title: Meningoencephalitis Comp Panel, S Performing Location: Focus Diagnostics, Specimen Requirements: Draw blood in a plain, red-top tube(s). (Serum gel tube is acceptable.) Spin down and send

More information

Request for Prior Authorization Growth Hormone (Norditropin

Request for Prior Authorization Growth Hormone (Norditropin Request for Prior Authorization Growth Hormone (Norditropin, Nutropin/AQ ) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Growth Hormone require a

More information

Test Definition: SAT24 Supersaturation Profile, 24 Hour, Urine

Test Definition: SAT24 Supersaturation Profile, 24 Hour, Urine Reporting Title: Supersaturation, U Performing Location: Rochester Specimen Requirements: Container/Tube: Plastic, 60-mL urine bottle Specimen Volume: 35 ml Collection Instructions: 1. Collect urine for

More information

Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements. In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the

More information

Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements. Immediate Action In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed

More information

Tests recently added to the NMS Labs test menu. New Tests are effective immediately.

Tests recently added to the NMS Labs test menu. New Tests are effective immediately. Immediate Action In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed

More information

Study of Serum Hepcidin as a Potential Mediator of the Disrupted Iron Metabolism in Obese Adolescents

Study of Serum Hepcidin as a Potential Mediator of the Disrupted Iron Metabolism in Obese Adolescents Study of Serum Hepcidin as a Potential Mediator of the Disrupted Iron Metabolism in Obese Adolescents Prof. Azza Abdel Shaheed Prof. of Child Health NRC National Research Centre Egypt Prevalence of childhood

More information

Type 2 Diabetes Mellitus in Adolescents PHIL ZEITLER MD, PHD SECTION OF ENDOCRINOLOGY DEPARTMENT OF PEDIATRICS UNIVERSITY OF COLORADO DENVER

Type 2 Diabetes Mellitus in Adolescents PHIL ZEITLER MD, PHD SECTION OF ENDOCRINOLOGY DEPARTMENT OF PEDIATRICS UNIVERSITY OF COLORADO DENVER Type 2 Diabetes Mellitus in Adolescents PHIL ZEITLER MD, PHD SECTION OF ENDOCRINOLOGY DEPARTMENT OF PEDIATRICS UNIVERSITY OF COLORADO DENVER Yes! Is Type 2 diabetes the same in kids as in adults? And No!

More information

April 28, RE: Immediate Action test change notification. Dear Valued Client:

April 28, RE: Immediate Action test change notification. Dear Valued Client: April 28, 2010 RE: Immediate Action test change notification Dear Valued Client: The following pages detail important information regarding a test requiring database modifications. Please be advised that

More information

PUBLICATIONS Abstracts and publications on the psychological data available.

PUBLICATIONS Abstracts and publications on the psychological data available. Page 1 of 9 Synopsis TITLE OF TRIAL : The Effects of Biosynthetic Human Growth Hormone Treatment in the Management of Children with Familial Short Stature. Protocol B: A Comparative Evaluation of Growth

More information

AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE 64th Annual Meeting

AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE 64th Annual Meeting Page 1 of 5 Please select Print from the file menu to print your Abstract. AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE 64th Annual Meeting Filename: 650582 Submission Type: Scientific Abstract (Oral/Poster)

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #440: Basal Cell Carcinoma (BCC)/Squamous Cell Carcinoma (SCC): Biopsy Reporting Time Pathologist to Clinician National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS

More information

How to approach a child with growth concern

How to approach a child with growth concern How to approach a child with growth concern Alaa Al Nofal, MD Assistant Professor of Pediatrics Pediatric Endocrinology Sanford Children Specialty Clinic Nothing to disclose Disclosure Objectives To understand

More information

PFIZER INC. Study Centre: One centre from Hungary enrolled subjects in this study

PFIZER INC. Study Centre: One centre from Hungary enrolled subjects in this study PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Why is my body not changing? Conflicts of interest. Overview 11/9/2015. None

Why is my body not changing? Conflicts of interest. Overview 11/9/2015. None Why is my body not changing? Murthy Korada Pediatrician, Pediatric Endocrinologist Ridge Meadows Hospital Surrey Memorial Hospital None Conflicts of interest Overview Overview of normal pubertal timing

More information

Metabolic, cardiovascular and anthropometric differences between prepubertal girls and boys

Metabolic, cardiovascular and anthropometric differences between prepubertal girls and boys Clinical Endocrinology (2014) 81, 238 243 doi: 10.1111/cen.12436 ORIGINAL ARTICLE Metabolic, cardiovascular and anthropometric differences between prepubertal girls and boys Ahila Ayyavoo*,, Jose G. B.

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority Quality ID #440: Basal Cell Carcinoma (BCC)/Squamous Cell Carcinoma (SCC): Biopsy Reporting Time Pathologist to Clinician National Quality Strategy Domain: Communication and Care Coordination Meaningful

More information

Tests recently added to the NMS Labs test menu. New Tests are effective immediately.

Tests recently added to the NMS Labs test menu. New Tests are effective immediately. Immediate Action In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed

More information

Diagnosing Growth Disorders. PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health

Diagnosing Growth Disorders. PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health Diagnosing Growth Disorders PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health Content Normal pattern of growth and its variation Using growth charts Interpreting auxological

More information

Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care

Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care Quality ID #250 (NQF 1853): Radical Prostatectomy Pathology Reporting National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process

More information

Marloes P. van der Aa, 1 Vera Hoving, 1 Ewoudt M. W. van de Garde, 2 Antonius de Boer, 3 Catherijne A. J. Knibbe, 2 and Marja M. J.

Marloes P. van der Aa, 1 Vera Hoving, 1 Ewoudt M. W. van de Garde, 2 Antonius de Boer, 3 Catherijne A. J. Knibbe, 2 and Marja M. J. Obesity Volume 216, Article ID 7852648, 7 pages http://dx.doi.org/1.1155/216/7852648 Clinical Study The Effect of Eighteen-Month Metformin Treatment in Obese Adolescents: Comparison of Results Obtained

More information

ENDOCRINE DISORDERS IN THALASSEMIA MAJOR: QUALITY OF LIFE BEYOND SURVIVAL

ENDOCRINE DISORDERS IN THALASSEMIA MAJOR: QUALITY OF LIFE BEYOND SURVIVAL ENDOCRINE DISORDERS IN THALASSEMIA MAJOR: QUALITY OF LIFE BEYOND SURVIVAL 1,2 Carmen Barbu, 1,2 Alice Albu, 3 Larisa Nitu, 3 Daniela Voicu, 1,3 Florentina Vladareanu, 2 Suzana Florea and 1,2 Simona Fica

More information

Everyday!!! Childhood Obesity

Everyday!!! Childhood Obesity Childhood Obesity S O U T H W E S T C O M M U N I T Y H E A L T H C E N T E R S E A R C H P R O J E C T L A C Y B I R D S E Y E R N, B S N ( F N P S T U D E N T ) F A I R F I E L D U N I V E R S I T Y

More information

Prior Authorization Criteria Form This form applies to Paramount Commercial Members Only. Non-Preferred Growth Hormone Products

Prior Authorization Criteria Form This form applies to Paramount Commercial Members Only. Non-Preferred Growth Hormone Products Prior Authorization Criteria Form This form applies to Paramount Commercial Members Only Criteria: P0078 Approved: 3/2017 Reviewed: Non-Preferred Growth Hormone Products Complete/review information, sign

More information

Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit

Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit Sotos and Tokar International Journal of Pediatric Endocrinology 2014, 2014:15 RESEARCH Open Access Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison

More information

NIH Public Access Author Manuscript Eur J Clin Nutr. Author manuscript; available in PMC 2009 November 11.

NIH Public Access Author Manuscript Eur J Clin Nutr. Author manuscript; available in PMC 2009 November 11. NIH Public Access Author Manuscript Published in final edited form as: Eur J Clin Nutr. 2004 April ; 58(4): 696 699. doi:10.1038/sj.ejcn.1601852. Gender differences in TNF-α levels among obese vs nonobese

More information

Hyperprolactinemia in A 15-Year-Old Girl with Primary Amenorrhea

Hyperprolactinemia in A 15-Year-Old Girl with Primary Amenorrhea Clin Pediatr Endocrinol 1996; 5(2), 61-66 Copyright (C) 1996 by The Japanese Society for Pediatric Endocrinology Hyperprolactinemia in A 15-Year-Old Girl with Primary Amenorrhea Toshihisa Okada, Soroku

More information

METABOLIC SYNDROME IN OBESE CHILDREN AND ADOLESCENTS

METABOLIC SYNDROME IN OBESE CHILDREN AND ADOLESCENTS Rev. Med. Chir. Soc. Med. Nat., Iaşi 2012 vol. 116, no. 4 INTERNAL MEDICINE - PEDIATRICS ORIGINAL PAPERS METABOLIC SYNDROME IN OBESE CHILDREN AND ADOLESCENTS Ana-Maria Pelin 1, Silvia Mǎtǎsaru 2 University

More information

Lipid and Insulin Levels in Obese Children: Changes with Age and Puberty

Lipid and Insulin Levels in Obese Children: Changes with Age and Puberty Risk Factors and Chronic Disease Lipid and Insulin Levels in Obese Children: Changes with Age and Puberty Orit Pinhas-Hamiel,* Liat Lerner-Geva,* Nancy M. Copperman, and Marc S. Jacobson Abstract PINHAS-HAMIEL,

More information

AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents

AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents Aetna Better Health 2000 Market Street, Suite 850 Philadelphia, PA 19103 AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents Revised April 2014 Growth

More information

March Molecular diagnostics. Update distribution changes. Billing and compliance. Hematology. Immunology. Referral testing

March Molecular diagnostics. Update distribution changes. Billing and compliance. Hematology. Immunology. Referral testing March 2016 Update distribution changes Billing and compliance Compliance Drug Analysis CPT change Hematology Hemoglobin A1c, Screening Reference Range Change Immunology Testing schedule changes Vitamin

More information

Growth hormone (GH) dose-dependent IGF-I response relates to pubertal height gain

Growth hormone (GH) dose-dependent IGF-I response relates to pubertal height gain Lundberg et al. BMC Endocrine Disorders (2015) 15:84 DOI 10.1186/s12902-015-0080-8 RESEARCH ARTICLE Growth hormone (GH) dose-dependent IGF-I response relates to pubertal height gain Open Access Elena Lundberg

More information

March Immunoglobulins, Total (IgA, IgE, IgG, IgM) Interleukin-6 (IL6) Protein Electrophoresis, CSF. Thyrotropin Receptor Antibody

March Immunoglobulins, Total (IgA, IgE, IgG, IgM) Interleukin-6 (IL6) Protein Electrophoresis, CSF. Thyrotropin Receptor Antibody University of Washington March 2012 TEST CHANGE Alpha 1-Antitrypsin Anti-IgE Receptor Antibody Anti-Mullerian Hormone Aquaporin-4 Receptor Antibody ColoSeq - Polyposis Complement testing, C3, C4 Everolimus

More information

The Turkish Journal of Pediatrics 2004; 46:

The Turkish Journal of Pediatrics 2004; 46: ---> The Turkish Journal of Pediatrics 2004; 46: 303-308 Original Influence of iodine supplementation on serum insulin-like growth factor-i (IGF-I) and IGF-binding protein-3 (IGFBP-3) levels in severe

More information

First Name. Specialty: Fax. First Name DOB: Duration:

First Name. Specialty: Fax. First Name DOB: Duration: Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:

More information

Influence of Leptin on Changes in Body Fat during Growth in African American and White Children

Influence of Leptin on Changes in Body Fat during Growth in African American and White Children Influence of Leptin on Changes in Body Fat during Growth in African American and White Children Maria S. Johnson,* Terry T-K. Huang,* Reinaldo Figueroa-Colon, James H. Dwyer,* and Michael I. Goran* Abstract

More information

Laboratory Testing for Pediatric Patients: Concerns, Challenges and Solutions

Laboratory Testing for Pediatric Patients: Concerns, Challenges and Solutions Laboratory Testing for Pediatric Patients: Concerns, Challenges and Solutions Joely Straseski PhD, MT(ASCP), DABCC, FACB Assistant Professor, University of Utah Medical Director, ARUP Laboratories Endocrinology

More information

AETNA BETTER HEALTH Prior Authorization guideline for Growth Hormone Agents

AETNA BETTER HEALTH Prior Authorization guideline for Growth Hormone Agents AETNA BETTER HEALTH Prior Authorization guideline for Growth Hormone Agents Growth Hormone and related agents Formulary: Omnitrope vials Non-Formulary: Genotropin, Humatrope, Saizen, Serostim, Tev-Tropin,

More information

The Adolescent: A Patient at Risk: Ovarian Failure in Adolescent Cancer Survivors

The Adolescent: A Patient at Risk: Ovarian Failure in Adolescent Cancer Survivors The Adolescent: A Patient at Risk: Ovarian Failure in Adolescent Cancer Survivors Avner Hershlag MD Professor and Chief Center for Human Reproduction North Shore LIJ Hofsra university School of Medicine

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Mecasermin Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5 References... 5 Effective Date... 5/15/2017 Next

More information

Pubertal insulin resistance has been well documented

Pubertal insulin resistance has been well documented Longitudinal Study on Pubertal Insulin Resistance Michael I. Goran 1 and Barbara A. Gower 2 Previous cross-sectional studies show that puberty is associated with a reduction in insulin sensitivity (S I

More information

The science behind igro

The science behind igro The science behind igro igro is an interactive tool that can help physicians evaluate growth outcomes in patients receiving growth hormone (GH) treatment. These pages provide an overview of the concepts

More information

Crescimento Variantes do normal e patológico

Crescimento Variantes do normal e patológico Manuel Fontoura Faculdade de Medicina do Porto Centro Hospitalar de S. João Endocrinologia Pediátrica e Diabetes Crescimento Variantes do normal e patológico Curso Pré-graduado de Pediatria Sociedade Portuguesa

More information

Aerobic Wound Culture and Stain

Aerobic Wound Culture and Stain Aerobic Wound Culture and Stain Order Name: C WOUN RTS Test Number: 6000153 Revision Date: 03/27/2014 Aerobic Wound Culture and Stain Culture Preferred 1 ml Tissue Sterile Screwtop Container Room Temperature

More information

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade Quality ID #99 (NQF 0391): Breast Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective

More information

2.0 Synopsis. Lupron Depot M Clinical Study Report R&D/09/093. (For National Authority Use Only) to Part of Dossier: Name of Study Drug:

2.0 Synopsis. Lupron Depot M Clinical Study Report R&D/09/093. (For National Authority Use Only) to Part of Dossier: Name of Study Drug: 2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: Name of Study Drug: Volume: Abbott-43818 (ABT-818) leuprolide acetate for depot suspension (Lupron Depot ) Name of

More information

Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements. Immediate Action In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed

More information

Effective Health Care Program

Effective Health Care Program Comparative Effectiveness Review Number 23 Effective Health Care Program Effectiveness of Recombinant Human Growth Hormone (rhgh) in the Treatment of Patients With Cystic Fibrosis Executive Summary Background

More information

Growth and DMD Endocrine aspects of care

Growth and DMD Endocrine aspects of care Growth and DMD Endocrine aspects of care Meilan Rutter, MB,BCh, FRACP Division of Endocrinology Cincinnati Children s Hospital Medical Center July 2007 Where are we now? Inactive Reactive Proactive CCHMC

More information

Injection Solution APP 100 mg/ml MULTI-DOSE IN 1VIAL, MULTI-DOSE / 20 ml IN 1 VIAL, MULTI-DOSE

Injection Solution APP 100 mg/ml MULTI-DOSE IN 1VIAL, MULTI-DOSE / 20 ml IN 1 VIAL, MULTI-DOSE Please use the product information below as a reference when considering your answers to the following items regarding your institution s pharmacy stock of cytarabine. Product NDC Dosage Form Labeler Name

More information

TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: HUMATROPE, NUTROPIN AQ, OMNITROPE, SAIZEN

TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: HUMATROPE, NUTROPIN AQ, OMNITROPE, SAIZEN TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: HUMATROPE, NUTROPIN AQ, OMNITROPE, SAIZEN STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING Date: Prescriber First & Last Name:

More information

27027 Tourney Road Valencia, CA 91355 800 421 7110 www.specialtylabs.com Test Updates September 25, 2009 Dear Colleague: Specialty Laboratories is pleased to announce a new assay, PT and PTT-LA Mixing

More information

Individual Study Table Referring to Item of the Submission: Volume: Page:

Individual Study Table Referring to Item of the Submission: Volume: Page: 2.0 Synopsis Name of Company: Abbott Laboratories Name of Study Drug: Meridia Name of Active Ingredient: Sibutramine hydrochloride monohydrate Individual Study Table Referring to Item of the Submission:

More information

January Billing and compliance. Chemistry. Help us help you. Referral testing. Additional CPT code changes announced for 2015

January Billing and compliance. Chemistry. Help us help you. Referral testing. Additional CPT code changes announced for 2015 January 2015 Billing and compliance Additional CPT code changes announced for 2015 Chemistry CA 27.29 conversion to CA 15-3 nearing completion Vitamin B12 and LD, Total specimen change Timed Urine Protein

More information

Growth of Visceral Fat, Subcutaneous Abdominal Fat, and Total Body Fat in Children

Growth of Visceral Fat, Subcutaneous Abdominal Fat, and Total Body Fat in Children Growth of Visceral Fat, Subcutaneous Abdominal Fat, and Total Body Fat in Children Terry T.-K. Huang,* Maria S. Johnson,* Reinaldo Figueroa-Colon, James H. Dwyer,* and Michael I. Goran* Abstract HUANG,

More information

AMH and measuring Ovarian reserve

AMH and measuring Ovarian reserve AMH and measuring Ovarian reserve Professor W Hamish Wallace Consultant Paediatric Oncologist Edinburgh Scotland UK hamish.wallace@nhs.net Ovarian Reserve? The Wallace-Kelsey Model (Five parameter asymmetric

More information

Failure of IGF-I and IGFBP-3 to diagnose growth hormone insuyciency

Failure of IGF-I and IGFBP-3 to diagnose growth hormone insuyciency Arch Dis Child 999;8:3 7 3 Failure of IGF-I and IGFBP-3 to diagnose growth hormone insuyciency H Mitchell, M T Dattani, V Nanduri, P C Hindmarsh, M A Preece, C G D Brook London Centre for Paediatric Endocrinology,

More information

Sandwell Early Numeracy Test

Sandwell Early Numeracy Test SENT Reports School: Test School Section: A, B, C, D, Group: Class 3OS No. Students: 6 Sandwell Early Numeracy Test Section A - Student Listing This report lists the results for each student from the selected

More information

DESCRIPTION: Percentage of final reports for screening mammograms that are classified as probably benign

DESCRIPTION: Percentage of final reports for screening mammograms that are classified as probably benign Quality ID #146 (NQF 0508): Radiology: Inappropriate Use of Probably Benign Assessment Category in Screening Mammograms National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS F INDIVIDUAL

More information

TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: GENOTROPIN & NORDITROPIN Texas Children s Health Plan Only

TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: GENOTROPIN & NORDITROPIN Texas Children s Health Plan Only TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: GENOTROPIN & NORDITROPIN Texas Children s Health Plan Only STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING Date: Prescriber First

More information

Judith Ross, 1 Peter A. Lee, 2 Robert Gut, 3 and John Germak Introduction

Judith Ross, 1 Peter A. Lee, 2 Robert Gut, 3 and John Germak Introduction Hindawi Publishing Corporation International Journal of Pediatric Endocrinology Volume 2010, Article ID 494656, 7 pages doi:10.1155/2010/494656 Research Article Factors Influencing the One- and Two-Year

More information

Growth Hormone plus Childhood Low- Dose Estrogen in Turner s Syndrome. N Engl J Med 2011;364: Present by R5 郭恬妮

Growth Hormone plus Childhood Low- Dose Estrogen in Turner s Syndrome. N Engl J Med 2011;364: Present by R5 郭恬妮 Growth Hormone plus Childhood Low- Dose Estrogen in Turner s Syndrome N Engl J Med 2011;364:1230-42. Present by R5 郭恬妮 Introduction Turner s syndrome : partial or complete X-chromosome monosomy, 1 in 2000

More information

Supplemental Table 1 Age and gender-specific cut-points used for MHO.

Supplemental Table 1 Age and gender-specific cut-points used for MHO. Supplemental Table 1 Age and gender-specific cut-points used for MHO. Age SBP (mmhg) DBP (mmhg) HDL-C (mmol/l) TG (mmol/l) FG (mmol/l) Boys 6-11 90th * 90th * 1.03 1.24 5.6 12 121 76 1.13 1.44 5.6 13 123

More information

Growth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka

Growth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka Growth hormone therapy for short stature in adolescents Growth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka K K K Gamage,

More information

2. Is the request for Humatrope? Y N [If no, skip to question 6.]

2. Is the request for Humatrope? Y N [If no, skip to question 6.] Pharmacy Prior Authorization AETA BETTER HEALTH FLORIDA Growth Hormone Agents This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date.

More information

The somatopause. What stops our growth and diminishes GH secretion?

The somatopause. What stops our growth and diminishes GH secretion? The somatopause What stops our growth and diminishes GH secretion? What extends or stops statural growth? Statural growth is extended if the early growth rate is slowed underfed adolescents grow for a

More information

March Monthly Update, Quest Diagnostics Nichols Institute, Valencia

March Monthly Update, Quest Diagnostics Nichols Institute, Valencia NEW TESTS Please Note: Not all test codes assigned to each assay are listed in the table of contents. Please refer to the complete listing on the page numbers indicated. Test Code Test Name Effective Date

More information

Growth Hormones DRUG.00009

Growth Hormones DRUG.00009 Market DC Growth Hormones DRUG.00009 Override(s) Prior Authorization Quantity Limit Approval Duration WPM PAB Center: Thirty (30) day exception for recently expired (within the past 45 days) growth hormone

More information

Growth Hormone Therapy

Growth Hormone Therapy Growth Hormone Therapy Policy Number: Original Effective Date: MM.04.011 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/23/2014 Section: Prescription Drugs Place(s)

More information

PhRMA Clinical Study Synopsis Protocol CTN / (A /A ) 21 August 2006 Final PFIZER INC.

PhRMA Clinical Study Synopsis Protocol CTN / (A /A ) 21 August 2006 Final PFIZER INC. PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Date: 24 April-2007 Trial ID: GHTUR/E/2 Version: 2 Integrated Clinical Trial Report Status: Final ICTR Synopsis Page: 1 of 5

Date: 24 April-2007 Trial ID: GHTUR/E/2 Version: 2 Integrated Clinical Trial Report Status: Final ICTR Synopsis Page: 1 of 5 ICTR Synopsis Page: 1 of 5 Synopsis TITLE OF TRIAL INDUCTION OF PUBERTY WITH 17 Β-ESTRADIOL IN GIRLS WITH TURNER SYNDROME. AN OPEN RANDOMISED TRIAL TRIAL CODE: GHTUR/E/2 INVESTIGATORS IN TOTAL, 35 PRINCIPAL

More information

ENDOCRINOLOGY. EXPECTED VALUES & S.I. Unit Conversion Tables

ENDOCRINOLOGY. EXPECTED VALUES & S.I. Unit Conversion Tables ENDOCRINOLOGY EXPECTED VALUES & S.I. Unit Conversion Tables ENDOCRINOLOGY EXPECTED VALUES AND S.I. UNIT CONVERSION TABLES TABLE OF CONTENTS Introduction....................................................

More information

TOP-DOWN DETERMINATION OF SERUM INSULIN-LIKE GROWTH FACTORS BY LC-MS

TOP-DOWN DETERMINATION OF SERUM INSULIN-LIKE GROWTH FACTORS BY LC-MS TOP-DOWN DETERMINATION OF SERUM INSULIN-LIKE GROWTH FACTORS BY LC-MS Richard KT Kam, Ph.D. Scientific Officer, Department of Chemical Pathology Prince of Wales Hospital Prince of Wales Hospital, Hong Kong

More information

Original Effective Date: 7/5/2007

Original Effective Date: 7/5/2007 Subject: Recombinant Human Growth Hormone: PEDIATRIC_GENETIC DISEASES with Primary Effects on Growth Turner syndrome Noonan syndrome Prader-Willi syndrome SHOX mutations DISCLAIMER Original Effective Date:

More information

Clinical Guideline ADRENARCHE MANAGEMENT OF CHILDREN PRESENTING WITH SIGNS OF EARLY ONSET PUBIC HAIR/BODY ODOUR/ACNE

Clinical Guideline ADRENARCHE MANAGEMENT OF CHILDREN PRESENTING WITH SIGNS OF EARLY ONSET PUBIC HAIR/BODY ODOUR/ACNE Clinical Guideline ADRENARCHE MANAGEMENT OF CHILDREN PRESENTING WITH SIGNS OF EARLY ONSET PUBIC HAIR/BODY ODOUR/ACNE Includes guidance for the distinction between adrenarche, precocious puberty and other

More information

This CNE activity is supported by an educational grant from Novo Nordisk Inc.

This CNE activity is supported by an educational grant from Novo Nordisk Inc. This CNE activity is supported by an educational grant from Novo Nordisk Inc. Objectives Differentiate between normal growth variants and growth variants that are linked to a disorder Describe the process

More information

Quality ID #225 (NQF 0509): Radiology: Reminder System for Screening Mammograms National Quality Strategy Domain: Communication and Care Coordination

Quality ID #225 (NQF 0509): Radiology: Reminder System for Screening Mammograms National Quality Strategy Domain: Communication and Care Coordination Quality ID #225 (NQF 0509): Radiology: Reminder System for Screening Mammograms National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

More information

Type 2 Diabetes in Adolescents

Type 2 Diabetes in Adolescents Type 2 Diabetes in Adolescents Disclosures Paid consultant, Eli Lilly, Inc, Pediatric Type 2 Diabetes Clinical Trials Outline The burden of diabetes Treatment and Prevention Youth Diabetes Prevention Clinic

More information

PROJECT Ntshembo: Improving adolescent health and interrupting mother-infant transfer of health risk in Africa. INDEPTH Network

PROJECT Ntshembo: Improving adolescent health and interrupting mother-infant transfer of health risk in Africa. INDEPTH Network PROJECT Ntshembo: Improving adolescent health and interrupting mother-infant transfer of health risk in Africa INDEPTH Network Overview Transitions across countries Transitions within countries - South

More information

and LHRH Analog Treatment in

and LHRH Analog Treatment in Endocrine Journal 1996, 43 (Suppl), S13-S17 Combined GH Short Children and LHRH Analog Treatment in TosHIAKI TANAKA***, MARL SATOH**, AND ITSURo HIBI* *Division of Endocrinology & Metabolism, National

More information

The National Diabetes Prevention Program in Washington State March 2012

The National Diabetes Prevention Program in Washington State March 2012 The National Diabetes Prevention Program in Washington State March 2012 Session Objectives 1. Overview of pre-diabetes. 2. Describe the Diabetes Prevention Program (DPP). 3. Eligibility for the DPP. 4.

More information

Youth4Health Project. Student Food Knowledge Survey

Youth4Health Project. Student Food Knowledge Survey Youth4Health Project Student Food Knowledge Survey Student ID Date Instructions: Please mark your response. 1. Are you a boy or girl? Boy Girl 2. What is your race? Caucasian (White) African American Hispanic

More information

METABOLIC CONSEQUENCES OF CHILDHOOD OBESITY

METABOLIC CONSEQUENCES OF CHILDHOOD OBESITY METABOLIC CONSEQUENCES OF CHILDHOOD OBESITY Suttipong Wacharasindhu Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand Lifestyle changes are among the many factors

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #325: Adult Major Depressive Disorder (MDD): Coordination of Care of Patients with Specific Comorbid Conditions National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI. PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #104 (NQF 0390): Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS

More information

TEST STATUS NOTIFICATION DATE: November 13, 2015 EFFECTIVE DATE: December 15, Test ID: SAT24

TEST STATUS NOTIFICATION DATE: November 13, 2015 EFFECTIVE DATE: December 15, Test ID: SAT24 TEST STATUS NOTIFICATION DATE: vember 13, 2015 EFFECTIVE DATE: December 15, 2015 SUPERSATURATION PROFILE, 24 HOUR, URINE Test ID: SSAT EXPLANATION: The current profile is being replaced with a new one

More information

Endocrine. Joe O Neil, MD, Chair

Endocrine. Joe O Neil, MD, Chair Endocrine Joe O Neil, MD, Chair Definitions Endocrine Section is comprised of 3 parts: Precocious Puberty Short Stature and Effect of Growth Hormone Obesity Puberty Definitions Puberty is defined as presence

More information

What we will cover. Evaluation of the Child with Suspected Pituitary Disease. ituitary

What we will cover. Evaluation of the Child with Suspected Pituitary Disease. ituitary Evaluation of the Child with Suspected Pituitary Disease Craig Alter, MD University of Pennsylvania Children s Hospital of Philadelphia What we will cover * What laboratory tests to order * MRI: common

More information

Supplemental Data: Detailed Characteristics of Patients with MKRN3. Patient 1 was born after an uneventful pregnancy. She presented in our

Supplemental Data: Detailed Characteristics of Patients with MKRN3. Patient 1 was born after an uneventful pregnancy. She presented in our 1 2 Supplemental Data: Detailed Characteristics of Patients with MKRN3 Mutations 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Patient 1 was born after an uneventful pregnancy. She presented

More information

EVALUATIONWEB 2014 DIRECTLY FUNDED CBO CLIENT-LEVEL DATA COLLECTION TEMPLATE

EVALUATIONWEB 2014 DIRECTLY FUNDED CBO CLIENT-LEVEL DATA COLLECTION TEMPLATE General instructions for completing the EvaluationWeb Directly Funded CBO Client-Level Data Collection Template This data collection template is provided to assist community-based organizations that receive

More information